Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from the U.S. Food and Drug Administration
Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from the U.S. Food and Drug Administration
Article Date
April 2, 2024
This article is featured on another website.
Go to article
January 26, 2026
Understanding the US FDA’s Special Designations and Approval Pathways
Recognizing the challenges of drug development, the US FDA has established several special designations and…
January 26, 2026
Understanding the US FDA’s Special Designations and Approval Pathways
Recognizing the challenges of drug development, the US FDA has established several special designations and…